NewAmsterdam Pharma Company NV - Warrants (15/11/2027) EBIT

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) (NAMSW) currently reports a EBIT of $-230M as of March 2026. That compares with $-260M in the prior-year period — up 10.1% year over year. That is below the sector sector average of $-69M. Use the charts on this page to explore NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s EBIT history and peer comparisons.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s EBIT increased from $-260M to $-230M — a 10.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s EBIT of $-230M is lower than the its sector sector average of $-69M. That is roughly 236.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) reported $-230M in EBIT as of March 2026. That compares with $-260M in the prior-year period — up 10.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-230M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-69M. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV - Warrants (15/11/2027), and consider following NAMSW for alerts when major investors trade the stock.